Author

Chad Pickering

Observed name: C. Pickering

OpenAlex ID: A5074866369

Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling

2024 · Chirag Dhar, Prasanna Ramachandran, et al. · British Journal of Cancer · 14

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy

2023 · Chad Pickering, Paul Aiyetan, et al. · Frontiers in Immunology · 12

Differential Peripheral Blood Glycoprotein Profiles in Symptomatic and Asymptomatic COVID-19

2022 · Chad Pickering, Bo Zhou, et al. · Viruses · 11

Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint inhibitor treatment benefit in metastatic malignant melanoma.

2022 · Klaus Lindpaintner, Alan Mitchell, et al. · Journal of Clinical Oncology · 5

Glycoproteomics as a powerful liquid biopsy-based screening tool for non-small cell lung cancer.

2022 · Alan Mitchell, Chad Pickering, et al. · Journal of Clinical Oncology · 5

1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER

2024 · D.A. Braun, Y. Wang, et al. · Annals of Oncology · 4

Liquid-biopsy-derived glycoproteomic profiling as a novel means for noninvasive diagnosis of ovarian cancer.

2022 · Danie Serie, Kaitlynn Moser, et al. · Journal of Clinical Oncology · 2

GlycoKnow Ovarian: a Glycoprotein-based, Serum Diagnostic to Distinguish Ovarian Cancers from Benign Pelvic Masses

2025 · Daniel Serie, Kaitlynn Moser, et al. · medRxiv · 1

43 Harnessing the power of glycoproteomics: a cutting-edge approach for predicting treatment efficacy in metastatic melanoma with immune checkpoint inhibitors

2023 · Yana G Najjar, Chad Pickering, et al. · Journal for ImmunoTherapy of Cancer · 1

1241P Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics

2023 · K. He, G. Absenger, et al. · Annals of Oncology · 1

Abstract 5314: A peripheral blood-based glycoproteomic predictor of checkpoint inhibitor treatment benefit in advanced non-small cell lung cancer

2023 · Klaus Lindpaintner, Chad Pickering, et al. · Cancer Research · 1

Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.

2022 · Danie Serie, Chad Pickering, et al. · Journal of Clinical Oncology · 1

40 Blood-based proteomic and glycoproteomic biomarkers exhibit promising additivity in predicting response in checkpoint inhibitor treated lung cancer

2025 · Chad Pickering, Andrew Quong, et al. · Journal for ImmunoTherapy of Cancer

741 Correlation between protein expression in immune cell populations and circulating glycopeptide biomarkers differs with response to checkpoint inhibitor treatment in advanced lung cancer

2025 · Andrew Quong, Chad Pickering, et al. · Journal for ImmunoTherapy of Cancer

P1.21-19 Potential Utilization of Serum Glycoproteomics as a Biomarker to Predict Survival Outcomes and irAEs in Advanced NSCLC Treated with ICI

2023 · L. Kim, M. Nam, et al. · Journal of Thoracic Oncology

P1.21-18 Potential Role of Serum Glycoproteomics in Predicting irAEs in NSCLC Patients Treated with Immunotherapy

2023 · L. Kim, M. Nam, et al. · Journal of Thoracic Oncology

Works count: 16

Citation count: 58

H-index: 5

I10-index: 3